Journal: BioMed Research International

Article Title: SEA Antagonizes the Imatinib-Meditated Inhibitory Effects on T Cell Activation via the TCR Signaling Pathway

doi: 10.1155/2014/682010

Figure Lengend Snippet: The cell proliferation and IL-2 production of Jurkat cells and PBMCs following TCR stimulation. (Control) Untreated Jurkat cells or PBMCs. (SEA) Cells were pretreated with SEA (20 ng/mL). (IM) Cells were pretreated with 40 nM imatinib. (SEA + IM) Cells were pretreated with SEA (20 ng/mL) for 24 h followed by 40 nM imatinib treatment for 15 min. Each group was stimulated with anti-CD3/CD28 coated beads at a cell : bead ratio of 5 : 1 for 24 h. Cell proliferation was assayed with the CCK-8 kit (a) and (b). The IL-2 level was assayed using a human IL-2 ELISA kit (c) and (d). The mean value and standard deviation of 3 independent experiments are shown.

Article Snippet: Imatinib mesylate (Glivec, STI571) was purchased from Selleck Chemicals (USA), and SEA was obtained from Sigma (USA).

Techniques: Control, CCK-8 Assay, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: BioMed Research International

Article Title: SEA Antagonizes the Imatinib-Meditated Inhibitory Effects on T Cell Activation via the TCR Signaling Pathway

doi: 10.1155/2014/682010

Figure Lengend Snippet: SEA pretreatment inhibited the reduction in imatinib-induced phosphorylation of Lck, ZAP70, and PLC γ 1 in Jurkat cells (a) and PBMCs (b). Densitometry (target protein : GAPDH ratio normalized to control) was conducted on three independent experiments in Jurkat cells (c) and PBMCs (d). Jurkat cells or PBMCs were pretreated in the absence or presence of SEA (20 ng/mL) followed by treatment with or without imatinib (40 nM), and cells were then stimulated with anti-CD3/CD28 coated beads for 15 min. Total cell extracts were resolved by SDS-PAGE and subjected to immunoblot analysis using phosphospecific antibodies as indicated.

Article Snippet: Imatinib mesylate (Glivec, STI571) was purchased from Selleck Chemicals (USA), and SEA was obtained from Sigma (USA).

Techniques: Phospho-proteomics, Control, SDS Page, Western Blot

Journal: Toxicology letters

Article Title: A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity.

doi: 10.1016/j.toxlet.2022.05.002

Figure Lengend Snippet: Fig. 3. Direct interaction of psoralen with ABL1. (A) Kinetics of psoralen binding to ABL1 determined by SPR, the kinetic parameters of KD were measured with BIAcore valuation software using a 1:1 binding model. (B) Three-dimensional molecular docking model of psoralen with the direct target protein ABL1 (PDB:2HYY).

Article Snippet: After stimulation for 24 h with a psoralen solution and specific concentrations of the ABL1 inhibitor imatinib (HY15463, MCE, USA), and an ABL1 agonist, DPH (HY12070, MCE, USA), the cells were digested with trypsin that did not contain EDTA and collected into a 1.5 mL centrifuge tube.

Techniques: Binding Assay, Software

Journal: Toxicology letters

Article Title: A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity.

doi: 10.1016/j.toxlet.2022.05.002

Figure Lengend Snippet: Fig. 8. To investigate the expression changes of Nrf2 and mTOR in HepG2 cells under the influence of an ABL1 inhibitor and agonist. (A) The effect of imatinib/DPH on the viability of HepG2 cells; (B) Western blot analysis of mTOR and Nrf2 in each group in HepG2 cells; (C) After 24 h exposure to imatinib/DPH in HepG2 cells, immunofluorescence staining was performed with Nrf2, mTOR antibody to assess the distribution of Nrf2, mTOR. Green fluorescence indicates Nrf2 expression, red fluorescence indicates mTOR expression, and blue fluorescence (DAPI) stained nuclei as a control. Scale bars: 50 µm. Normalized to ± β-action, All Data are shown as mean ± SD (n = 3). “* ” indicates statistically significant difference with the control group. * and # P < 0.05, * * and ## P < 0.01, * ** and ### P < 0.001 versus the psoralen alone group.

Article Snippet: After stimulation for 24 h with a psoralen solution and specific concentrations of the ABL1 inhibitor imatinib (HY15463, MCE, USA), and an ABL1 agonist, DPH (HY12070, MCE, USA), the cells were digested with trypsin that did not contain EDTA and collected into a 1.5 mL centrifuge tube.

Techniques: Expressing, Western Blot, Immunofluorescence, Staining, Fluorescence, Control

Journal: Toxicology letters

Article Title: A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity.

doi: 10.1016/j.toxlet.2022.05.002

Figure Lengend Snippet: Fig. 9. To investigate the expression changes of Nrf2 and mTOR in L02 cells under the influence of ABL1 inhibitor and agonist. (A) The effect of imatinib/DPH on the viability of L02 cells; (B) Western blot analysis of mTOR and Nrf2 in each group in L02 cells; (C) After 24 h of exposure to imatinib/DPH in L02 cells, immuno fluorescence staining was performed with Nrf2, mTOR antibodies to evaluate the distribution of Nrf2, mTOR. Green fluorescence indicates Nrf2 expression, red fluorescence indicates mTOR expression, and blue fluorescence (DAPI) stained nuclei as a control. Scale bars: 50 µm. Normalized to ± β-action, All Data are shown as mean ± SD (n = 3). “* ” indicates statistically significant difference with the control group. * and # P < 0.05, * * and ## P < 0.01, * ** and ### P < 0.001 versus the psoralen alone group.

Article Snippet: After stimulation for 24 h with a psoralen solution and specific concentrations of the ABL1 inhibitor imatinib (HY15463, MCE, USA), and an ABL1 agonist, DPH (HY12070, MCE, USA), the cells were digested with trypsin that did not contain EDTA and collected into a 1.5 mL centrifuge tube.

Techniques: Expressing, Western Blot, Fluorescence, Staining, Control

Journal: Cellular and Molecular Gastroenterology and Hepatology

Article Title: CMTM3 Promotes Colitis-associated Carcinogenesis via CLTC Stabilization and Modulation of VE-cadherin

doi: 10.1016/j.jcmgh.2025.101528

Figure Lengend Snippet: CMTM3 is a potential therapeutic target for UC. ( A ) A schematic overview of imatinib treatment. Starting from the first day of DSS, Imatinib mesylate (50 mg/kg) dissolved in PBS is administered intraperitoneally once a day until the final day of DSS treatment. The application of PBS served as a control. ( B ) Body weight was initially measured (day 0) and monitored daily thereafter throughout the experiment. ( C ) DAI scores of the 4 groups. ( D ) Representative images of hematoxylin and eosin staining of colon tissue. ( E ) Histologic scores. Scale bar = 100 μm. n = 3–5. Data is representative of 2 experiments with similar results. The data represents the mean ± SD, and statistical significance was determined by 1-way ANOVA with Tukey’s multiple comparisons test. ∗∗ P < .01 and ∗∗∗ P < .001; ns represents no significant difference.

Article Snippet: Starting from the first day of DSS, imatinib mesylate (50 mg/kg, HY-50946, MedChemExpress) dissolved in PBS was administered intraperitoneally once a day until the final day of DSS-induced colitis.

Techniques: Control, Staining